RxDoctor Payments Data

Kelvin Chou, MD

Neurology · Ann Arbor, MINPI 1376539791

Payments from drug & device makers

$68,443in general payments, 2019–2025

Across 96 payments — averaging $712.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$30K
  • Abbott$30K
  • Boston Scientific$4K
  • Avion Pharmaceuticals$2K
  • Bayer$2K
  • Amneal Pharmaceuticals LLC$1K
  • plus $228 from 2 others
$8,951in research payments, 2019–2025

Across 4 payments — averaging $2237.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$8K
  • Eli Lilly$863

What the payments were for

  • Consulting fees$18,32036%
  • Speaking & faculty fees$20,69640%
  • Travel & lodging$10,95621%
  • Food & beverage$1,6103%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,443 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$41,565
Medicare patients
193
Services billed
637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate26$162,227
RytaryCarbidopa/Levodopa38$68,015
Carbidopa-LevodopaCarbidopa/Levodopa640$44,079
Carbidopa-Levodopa ErCarbidopa/Levodopa131$14,002
Rasagiline Mesylate59$10,337
Entacapone18$9,145
Carbidopa25$6,463
Ropinirole ErRopinirole Hcl50$6,188
AmantadineAmantadine Hcl66$5,301
Propranolol Hcl ErPropranolol Hcl41$3,662
Pramipexole DihydrochloridePramipexole Di-Hcl101$2,894
Primidone41$2,077
Donepezil Hcl92$1,470
Gabapentin86$1,440
Ropinirole Hcl34$1,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$79$162,22726 claims
Amneal Pharmaceuticals LLCRytary$1,221$68,01538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.

Other neurology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →